1-(吲哚-2-羰基)-哌啶 | 73195-98-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 1-(吲哚-2-羰基)-哌啶
• 英文名称: (1H-indol-2-yl)(piperidin-1-yl)methanone
• 英文别名: 1H-indol-2yl-piperidin-1-yl-methanone；1H-indol-2-yl(piperidin-1-yl)methanone
• CAS: 73195-98-9
• 化学式: C₁₄H₁₆N₂O
• mdl: MFCD00451317
• 分子量: 228.294
• InChiKey: COUDZEQUWDSUCD-UHFFFAOYSA-N

物化性质

• 熔点：
  165-166 °C
• 沸点：
  445.5±18.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.357
• 拓扑面积：
  36.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(吲哚-2-羰基)-哌啶 在 哌啶 、 邻二氯苯 、 三氯氧磷 作用下， 生成 1-[3-(3-methyl-2,5-dioxo-imidazolidin-4-ylidenemethyl)-indole-2-carbonyl]-piperidine
  参考文献：
  名称：

  Derivatives of Indole-2-carboxylic Acid

  摘要：

  DOI：

  10.1021/ja01178a503
• 作为产物：
  描述：

  2-nitrocinnamic acid 在 吡啶 、 双(乙腈)氯化钯(II) 、 1,10-菲罗啉 、 草酰氯 、 甲酸苯酯 、 三乙胺 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 35.0h， 生成 1-(吲哚-2-羰基)-哌啶
  参考文献：
  名称：

  使用甲酸酯作为 CO 替代物通过硝基化合物的还原环化合成吲哚

  摘要：

  描述了使用烷基和苯基甲酸酯作为 CO 替代物从适当取代的硝基芳烃制备吲哚和其他N-杂环的非常有效、通用和可扩展的方案。使用甲酸苯酯，产物的分离产率通常高于以前使用气态 CO 实现的产率。通过动力学和机理研究阐明了甲酸苯酯的脱羰反应和环化反应的机理。

  DOI：

  10.1002/ejoc.202100789

文献信息

• 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer
  申请人：Huesca Mario

  公开号：US20100168417A1

  公开（公告）日：2010-07-01

  2-indolyl imidazo[4,5-d]phenanthroline compounds of Formula I that are capable of intracellular chelation of transition metals and of exerting antiproliferative effects in cancer cells, that are cytostatic and/or cytotoxic, are provided. Compounds of Formula I can also induce apoptosis in cancer cells and are thus capable of exerting a cytotoxic effect on cancer cells. The compounds of Formula I are also capable of selectively inhibiting the proliferation of one or more of prostate cancer cells, colon cancer cells, non-small lung cancer cells and leukemia cells. The compounds of Formula I are also capable of increasing the expression of the zinc-regulated tumour suppressor, KLF4 and thus are useful in inhibiting the proliferation of cancer cells in which KLF4 functions as a tumour-suppressor, including, but not limited to, bladder cancer, cancers of the gastrointestinal tract and various leukemias.

  提供了能够在细胞内与过渡金属螯合并对癌细胞产生抗增殖作用的Formula I的2-吲哚基咪唑并[4,5-d]菲啰啉化合物，这些化合物具有细胞静止和/或细胞毒作用。Formula I的化合物还可以诱导癌细胞凋亡，因此能够对癌细胞产生细胞毒作用。Formula I的化合物还能够选择性地抑制前列腺癌细胞、结肠癌细胞、非小细胞肺癌细胞和白血病细胞中的一个或多个的增殖。Formula I的化合物还能够增加锌调节的肿瘤抑制基因KLF4的表达，因此在抑制KLF4作为肿瘤抑制基因发挥作用的癌细胞的增殖方面具有用处，包括但不限于膀胱癌、胃肠道癌和各种白血病。
• Synthesis of N-Heterocycles by Reductive Cyclization of Nitro Compounds using Formate Esters as Carbon Monoxide Surrogates
  作者：Dario Formenti、Francesco Ferretti、Fabio Ragaini

  DOI：10.1002/cctc.201701214

  日期：2018.1.9

  A series of alkyl and aryl formate esters were evaluated as CO sources in the Pd‐ and Pd/Ru‐catalyzed reductive cyclization of substituted nitro compounds to afford heterocycles, especially indoles. Phenyl formate was found to be the most effective, and it allowed the desired products to be obtained in excellent yields, often higher than those previously reported with pressurized CO. Through detailed

  在Pd和Pd / Ru催化的取代硝基化合物的还原环化反应中，评估了一系列甲酸烷基酯和芳基酯作为CO的来源，以提供杂环，尤其是吲哚。人们发现甲酸苯甲酸是最有效的，它可以以优异的收率获得所需的产物，通常比以前用加压CO报道的要高。通过详细的实验和动力学研究，我们能够区分金属催化的碱介导的甲酸苯酯的活化，并证实仅碱可有效催化其脱羰基作用。
• INDOLES
  申请人：Bissantz Caterina

  公开号：US20080139549A1

  公开（公告）日：2008-06-12

  The present invention is concerned with novel indol-2-yl-carbonyl-piperidine derivatives as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful in the prevention and/or treatment of anxiety and depressive disorders and other diseases. Present invention is concerned with compounds of the general formula (I) wherein R 1 to R 6 , R 8 to R 14 , R 12′ , R 13′ , X and Y are as defined in the specification.

  本发明涉及作为V1a受体拮抗剂的新型吲哚-2-基-羰基-哌啶衍生物，其制备方法，含有它们的药物组合物以及它们作为药物的用途。本发明的活性化合物在预防和/或治疗焦虑和抑郁症等疾病方面具有用途。本发明涉及通式(I)的化合物，其中R1至R6，R8至R14，R12′，R13′，X和Y如规范中所定义。
• Amide derivatives as NMDA receptor antagonists
  申请人：RICHTER GEDEON VEGYESZETI GYAR RT.

  公开号：US20030199552A1

  公开（公告）日：2003-10-23

  New Formula (I) compounds are disclosed having NR2B selective NMDA receptor antagonist activity 1 wherein one of the neighboring R 1 , R 2 , R 3 and R 4 groups is OH or NH2 and the others are each hydrogen , or two of the neighboring R 1 , R 2 R 3 and R 4 groups in given case together with one or more identical or different additional hetero atom and —CH═ and/or —CH 2 — groups forms a 5-6 membered homo- or heterocyclic ring, preferably pyrrole, pyrazole, imidazole, oxazole, oxo-oxazolidine, or 3-oxo-1,4-oxazine ring, and the other two of R 1 , R 2 , R 3 and R 4 groups are is hydrogen atoms, R 5 and R 6 together with the nitrogen between them form a saturated or unsaturated, 4-6 membered heterocyclic ring, which is substituted by hydroxy group, and/or in given case phenyl or phenoxy, phenyl-(C 1 -C 4 alkyl), phenyl-(C 1 -C 4 alkoxy), phenoxy-(C 1 -C 4 alkyl), anilino, phenyl-(C 1 -C 4 alkylamino), [phenyl-(C 1 -C 4 alkyl)]-amino, benzoyl, hydroxy-diphenylmethyl, C 1 -C 4 alkoxycarbonyl-phenoxymethyl or benzhydrylidene group, optionally substituted on the aromatic ring by one or more halogen atom, cyano or hydroxy group, C 1 -C 4 alkyl or C 1 -C 4 alkoxy group, X is independently oxygen, —NH— or a CH2 group, Y is independently a nitrogen atom or a —CH— group, and the salts thereof formed with acids and bases.

  揭示了具有NR2B选择性NMDA受体拮抗活性的新配方(I)化合物，其中相邻的R1、R2、R3和R4基团中的一个是OH或NH2，其他基团均为氢，或者在某些情况下，相邻的R1、R2、R3和R4基团中的两个与一个或多个相同或不同的额外杂原子和—CH和/或—CH2—基团一起形成5-6元素的同源或异源环，优选为吡咯、吡唑、咪唑、噁唑、噁唑烷酮或3-氧代-1,4-噁唑环，并且R1、R2、R3和R4中的另外两个基团是氢原子，R5和R6与它们之间的氮原子一起形成饱和或不饱和的、4-6元素的杂环，该环被羟基取代，或者在某些情况下为苯基或苯氧基、苯基-(C1-C4烷基)、苯基-(C1-C4氧基)、苯氧基-(C1-C4烷基)、苯胺基、苯基-(C1-C4烷基氨基)、[苯基-(C1-C4烷基)]-氨基、苯甲酰基、羟基-二苯甲基、C1-C4烷氧羰基-苯氧基甲基或苯甲亚乙基基团取代的芳环，该芳环上可以进一步取代一个或多个卤素原子、氰基或羟基、C1-C4烷基或C1-C4氧基基团，X独立地为氧、—NH—或CH2基团，Y独立地为氮原子或—CH—基团，以及与酸和碱形成的盐。
• [EN] AMIDE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS<br/>[FR] DERIVES AMIDIQUES COMME ANTAGONISTES DU RECEPTEUR NMDA
  申请人：RICHTER GEDEON VEGYESZET

  公开号：WO2002034718A1

  公开（公告）日：2002-05-02

  The invention relates to new NR2B selective NMDA receptor antagonist carboxylic acid amide derivatives of formula (I) as well as the recemates, optical antipodes and the salts thereof formed with acids and bases. Fruthermore objets of the present invention are the pharmaceutical compositions containing compounds of formula (I) or the salts thereof as active ingredients, as well as the synthesis of compounds of formula (I), and the chemical and pharmaceutical manufacture of medicaments containing these compounds, as well as the method of treatments with these compounds, which means administering to a mammal to be treated - including human - effective amount/amounts of compounds of formula (I) of the present invention as such or as medicament. The new carboxylic acid amide derivatives of formula (I) of the present invention are highly effective and selective antagonists of NMDA receptor, and moreover most of the compounds are selective antagonist of NR2B subtype of NMDA receptor.

  本发明涉及公式（I）的新型NR2B选择性NMDA受体拮抗剂羧酸酰胺衍生物，以及与酸和碱形成的外消旋体，光学对映体和其盐。此外，本发明的目标是含有公式（I）化合物或其盐作为活性成分的制药组合物，以及公式（I）化合物的合成，以及含有这些化合物的药物的化学和制药制造，以及使用这些化合物的治疗方法，即向待治疗的哺乳动物（包括人类）施用本发明的化合物的有效量/量，作为药物或单独使用。本发明的新型羧酸酰胺衍生物的公式（I）是高效和选择性的NMDA受体拮抗剂，而且大多数化合物是NMDA受体NR2B亚型的选择性拮抗剂。